Pricing Log in Create free account

Attovia Therapeutics, Inc. (ATTO) vs Janux Therapeutics, Inc. (JANX)

Attovia Therapeutics, Inc. and Janux Therapeutics, Inc. are both Biotechnology companies. Attovia Therapeutics, Inc. and Janux Therapeutics, Inc. are of similar size ($764.8M and $758.1M). Across the 2 metrics below, Attovia Therapeutics, Inc. leads on 1 and Janux Therapeutics, Inc. on 1.

Valuation

Metric ATTO JANX Biotechnology median
P/E — n/m 11.58
P/S n/m 23.60 9.61
P/B n/m 0.86 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m 1.07 0.72
EV/Sales n/m (4.81) 9.43
Earnings yield — (12.77%) (32.28%)
Free cash flow yield 0.00% (6.90%) (22.27%)

Profitability

Metric ATTO JANX Biotechnology median
Gross margin — 100.00% 68.81%
Operating margin — (419.24%) 0.00%
Net margin — (299.95%) 0.00%
Free cash flow margin — (162.70%) 0.00%
Return on equity — (10.58%) (50.30%)
Return on assets — (9.94%) (45.47%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ATTO JANX Biotechnology median
Revenue growth (TTM) — 214.40% 6.78%
EPS growth (last fiscal year) — (42.97%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric ATTO JANX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.39 17.69 4.74
Net debt to EBITDA — 5.58 1.01

Dividend

Metric ATTO JANX Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric ATTO JANX Biotechnology median
Market cap 764.77m 758.06m 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack